NEW YORK (GenomeWeb) – Biocartis announced today that it has received an exclusive worldwide license for EGFR ectodomain mutations that have been shown to determine responses to targeted therapy for patients with metastatic colorectal cancer (mCRC).
NEW YORK (GenomeWeb) – Biocartis announced today that it has received an exclusive worldwide license for EGFR ectodomain mutations that have been shown to determine responses to targeted therapy for patients with metastatic colorectal cancer (mCRC).
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.